Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MyomoMYO -6.88%55 3-Year EBITDA Growth Rate is 40.50% as of Jun. 2026, which is 29% below its 10-year median of 57.00. GuruFocus rates MYO with a GF Score™ of 55/100 and a GF Value™ of $3.23 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Myomo ranks better than 84.01% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 45.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Myomo was 59.10% per year. The lowest was -7.50% per year. And the median was 57.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Myomo 3-Year EBITDA Growth Rate Related Terms
MYO vs NNOX, SRTS, POSC: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Myomo's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myomo 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Myomo's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Myomo's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.50% mean?
Myomo (MYO) has a 3-Year EBITDA Growth Rate of 40.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Myomo and its competitors. This is 29% below median its historical median of 57.00. According to the industry distribution chart, Myomo ranks #110 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 16%.
Is Myomo's 3-Year EBITDA Growth Rate too high?
Myomo's current 3-Year EBITDA Growth Rate of 40.50% is 29% below median its 10-year median of 57.00. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Myomo's value of 40.50% is 412.7% above this industry median. Based on the distribution chart, Myomo ranks #110 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Myomo has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's 3-Year EBITDA Growth Rate compare to NNOX and SRTS?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #110 out of 688 companies for 3-Year EBITDA Growth Rate. This places Myomo in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.90. Myomo's value of 40.50% is 412.7% above this benchmark. While the company's 10-year median is 57.00 vs. the industry median of 7.90, Myomo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myomo's current 3-Year EBITDA Growth Rate of 40.50% is 412.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Myomo and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myomo's current 3-Year EBITDA Growth Rate is 40.50%, which is 29% below median its own 10-year median of 57.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.23, compared to a current price of $1.49 — trading 53.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 40.50%, which is 29% below median its 10-year median of 57.00 and 412.7% above the Medical Devices & Instruments industry median of 7.90. Myomo's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Myomo (MYO), the current 3-Year EBITDA Growth Rate is 40.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myomo (MYO) Overvalued in 2026?
Based on GuruFocus' analysis, Myomo stock appears to be undervalued.
The current stock price of $1.49 is trading 53.9% below its estimated GF Value™ of $3.23.
GuruFocus considers Myomo to be Possible Value Trap.
Key valuation signals for MYO:
3-Year EBITDA Growth Rate: 40.50% (29% below median its 10-year median of 57.00)
GF Value™: $3.23 vs. price of $1.49 (53.9% below fair value)
Industry Position: 412.7% above the Medical Devices & Instruments median (#110 of 688)
No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
55GF Score
Get the complete analysis for MYO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYO has been successfully added to your 
